Tenon Medical Expands IP Portfolio to 29 U.S. and 9 International Patents
Tenon Medical received USPTO Notices of Allowance for multiple patents expected to issue in 2026, building on ten patents granted in 2025 and bolstering its Catamaran SI Joint fusion IP. The portfolio now stands at 29 U.S. and 9 international patents with 31 pending, including 16 U.S. from SImmetry acquisition.
1. Strategic Patent Allowances
Tenon Medical received Notices of Allowance from the USPTO for multiple patent applications expected to issue in 2026, reinforcing protection for its Catamaran SI Joint Fusion System. These allowances build on the ten patents granted in 2025, underscoring the company’s focus on novel sacro-pelvic fusion technologies.
2. Expanded Patent Portfolio
The current portfolio comprises 29 issued U.S. patents and 9 international patents, with 31 pending U.S. and foreign applications. This expansion enhances the company’s competitive moat and supports its long-term growth objectives by securing key systems and methods.
3. SImmetry Acquisition Contribution
Acquisition of SIVantage's SImmetry and SImmetry+ systems brought in 16 U.S. patents covering lateral SI joint fusion approaches. This strategic asset adds a differentiated fusion technique that complements the Catamaran platform and broadens clinical applications.
4. Innovation Pipeline and Growth Outlook
With a robust pipeline of additional patent applications expected to issue, Tenon Medical aims to drive procedure adoption and revenue growth. The strengthened IP portfolio underpins the company’s strategy to deliver less invasive sacroiliac joint solutions and create shareholder value.